SET8 expression is associated with overall survival in gastric cancer

X.L. Shi[1], Z.J. Guo[2], X.L. Wang[3], X.L. Liu[1] and G.F. Shi[4]

[1]Department of Pain Medicine and Rehabilitation,
The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
[2]Department of Gastroenterology and Hepatology,
The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
[3]Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
[4]Department of Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Corresponding author: G.F. Shi
E-mail: gaofengs62@sina.com

Genet. Mol. Res. 14 (4): 15609-15615 (2015)
Received August 6, 2015
Accepted October 25, 2015
Published December 1, 2015
DOI http://dx.doi.org/10.4238/2015.December.1.12

ABSTRACT. SET8, a member of the SET domain-containing methyltransferase, has been implicated in various biological processes. In this study, SET8 was immunostained in 100 samples of gastric cancer tissues and semi-quantified using the HSCORE method to determine the predictive value of SET8 expression levels for gastric cancer outcome. The relationship between SET8 expression and the 5-year survival rate of gastric cancer patients was assessed. High expression of SET8 was associated with a shorter survival time in gastric cancer patients, and the level of SET8 expression was found to be an independent predictor of gastric cancer outcome (relative risk = 1.939; 95% confidence interval = 1.025-3.668; P = 0.042). Analysis of SET8 levels may help in the identification of patient subgroups that are at high risk for poor disease outcomes.

Key words: Gastric cancer; Predictor; SET8; Cancer survival

